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Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. Although recent therapeutic 
advances have prolonged patient survival, the prognosis remains dismal. C-MER proto-oncogene tyrosine 
kinase (MERTK) is a receptor tyrosine kinase with oncogenic properties that is often overexpressed or acti-
vated in various malignancies. Using both protein immunohistochemistry and microarray analyses, we 
demonstrate that MERTK expression correlates with disease progression. MERTK expression was highest 
in metastatic melanomas, followed by primary melanomas, while the lowest expression was observed in nevi. 
Additionally, over half of melanoma cell lines overexpressed MERTK compared with normal human melano-
cytes; however, overexpression did not correlate with mutations in BRAF or RAS. Stimulation of melanoma 
cells with the MERTK ligand GAS6 resulted in the activation of several downstream signaling pathways includ-
ing MAPK/ERK, PI3K/AKT, and JAK/STAT. MERTK inhibition via shRNA reduced MERTK-mediated down-
stream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human 
melanoma murine xenograft model. Treatment of melanoma cells with UNC1062, a novel MERTK-selective 
small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, 
induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells. 
This work establishes MERTK as a therapeutic target in melanoma and provides a rationale for the continued 
development of MERTK-targeted therapies.
Introduction
Although early cutaneous melanoma is usually curable with sur-
gery, distant metastatic melanoma is an aggressive cancer with 
a median overall survival time of less than 1 year. In 2012, over 
75,000 new melanoma diagnoses were expected and over 9,000 
deaths were projected (1). Advances in the understanding of dis-
tinct melanoma subtypes as well as melanoma immunobiology 
have resulted in 2 FDA-approved therapies for metastatic mela-
noma in 2011: vemurafenib, an inhibitor of mutant BRAF — an 
oncogene present in approximately 50% of melanomas — and 
ipilimumab, a monoclonal antibody that targets CTLA-4 (2–4). 
Despite these rather impressive developments, the overall clini-
cal benefit is limited to either small subgroups of patients who 
may be cured by immunotherapies or to a subset of patients with 
BRAF-mutant melanoma, most of whom will eventually develop 
resistance to molecularly targeted therapies (5–9). This implies 
the need to better understand melanoma biology and identify 
additional molecular targets that may be amenable to therapeutic 
manipulation.
Receptor tyrosine kinases (RTKs) are frequently ectopically 
expressed, overexpressed, or hyperactivated in tumor cells and are 
therefore attractive targets for cancer therapy. C-MER proto-on-
cogene tyrosine kinase (MERTK), a member of the TAM (TYRO, 
AXL, MERTK) family of RTKs, has been characterized as a ther-
apeutic target in hematopoietic malignancies and several solid 
tumors including lung, prostate, and brain (10–13). As a potent 
mediator of prosurvival and antiapoptotic signaling pathways, 
MERTK is an upstream activator of both ERK1/2 and AKT. Addi-
tional signaling pathways that lead to antiinflammatory cytokine 
production as well as enhanced migration and invasion have 
been identified downstream of MERTK (11, 14, 15). A phosp-
hoproteomic study identified MERTK and other TAM receptors 
as commonly activated RTKs in melanoma, however no studies 
have reported on the function of MERTK in melanoma (16). The 
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role of other TAM receptors in melanoma has been described, 
suggesting that MERTK may also have a significant role in mel-
anoma development and progression. TYRO3 was identified as 
an overexpressed receptor in melanoma, a regulator of MITF, and 
a contributor to the proliferative, antiapoptotic, chemoresistant, 
and tumorigenic phenotypes of melanoma cells (17). In another 
study, AXL was commonly expressed in NRAS-mutant melanomas 
lacking MITF expression and contributed to a migratory and inva-
sive phenotype (18). In addition, Sensi et al. found that melanoma 
cells often secrete GAS6, a ligand of TAM receptors, indicating 
a mechanism of TAM autocrine signaling in melanoma. Taken 
together, these observations support the investigation of MERTK 
as a potential therapeutic target in melanoma.
Here, we report that MERTK expression increases with 
nevus-to-melanoma disease progression and is frequently 
overexpressed in melanoma cell lines. We propose an oncogenic 
role for MERTK in melanoma and demonstrate the suppression 
of MERTK-mediated signaling, colony formation, and tumorigen-
esis when MERTK expression is inhibited. Furthermore, pharma-
cologic targeting of MERTK in melanoma cells using UNC1062, a 
novel MERTK-selective small-molecule tyrosine kinase inhibitor, 
inhibited MERTK activation and subsequent signaling down-
stream of ligand-stimulated MERTK, induced apoptosis, and 
inhibited colony formation and invasion. These studies establish 
a potential oncogenic role for MERTK in melanoma and validate 
MERTK as a novel melanoma therapeutic target.
Results
MERTK expression increases with melanoma progression from nevus to 
metastatic disease. Although MERTK expression has been previously 
demonstrated in several melanoma cell lines (16), its expression 
in melanoma tissues has not been previously reported. To inves-
tigate the pattern and expression levels of MERTK during nevus-
to- melanoma progression, 2 independent tissue microarrays 
Figure 1
MERTK expression in nevus and melanoma tissues. (A) Box plots of MERTK expression in nevus, primary, and metastatic melanoma human 
samples. AQUA score of MERTK expression for each of the TMA cores representing nevi, primary, and metastatic melanoma were calculated 
in S100-positive cells and were normalized using logarithmic transformation. (B) Representative tissue cores from the nevus-to-melanoma 
TMA. Original magnification, ×20. Core H&E-stained images (top). Merged images (RGB) showing S100 staining pseudocolored with green 
and MERTK protein pseudocolored with red (bottom). (C) MERTK expression in a representative tissue section from a patient who underwent 
craniotomy for melanoma brain metastases. Tissues were stained for MERTK using alkaline phosphatase (red) detection and counterstained 
with hematoxylin. Original magnification, ×40. (D) Representative tissue core from the UNC metastatic melanoma TMA stained with H&E (left) 
and merged image showing staining with CD68 (pseudocolored with green), MERTK protein (pseudocolored with red), and Hoechst (blue, 
right). (E) Gene expression analysis of MERTK transcript in patient tissue samples from the GSE7553 microarray dataset (*P < 0.05, Tukey’s 
multiple comparison test).
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(TMAs) were stained with an antibody against MERTK protein, 
and immunofluorescence was assessed in S100-positive melano-
cyte lineage cells. A previously described nevus-to-melanoma TMA 
(19) and a metastatic melanoma TMA produced at the University 
of North Carolina (UNC) were used to determine MERTK expres-
sion in nevi (n = 17), primary melanomas (n = 41), and metastases 
(n = 94). As shown in Figure 1A, two-stain immunofluorescence 
analysis revealed that MERTK protein expression is low in nevi, 
but is significantly increased in primary melanomas and even more 
so in metastatic melanomas (trend test via linear regression 0.765, 
P < 0.0001). Figure 1B shows representative cores from nevi, pri-
mary, and metastatic melanoma tumor tissues that were stained 
with antibodies against MERTK and S100 and counterstained 
with Hoechst 33258. Immunohistochemical analysis of MERTK 
in tumor tissues from patients who had undergone craniotomy for 
melanoma brain metastases showed that MERTK was detectable 
in melanoma cells in 28% (8 of 29) cases. Figure 1C shows a repre-
sentative tissue section obtained from a patient who underwent 
craniotomy for melanoma brain metastases.
Both the staining pattern of the melanoma tissue microarrays 
and the morphology of MERTK-positive cells indicate that 
MERTK is not only expressed by melanoma cells, but is also 
expressed by other cells with monocytoid features (Figure 1D), 
as we have previously reported (20). To assess whether MERTK is 
also expressed by macrophages that infiltrate melanoma tumors, 
the UNC metastatic melanoma TMA was stained with antibodies 
against MERTK and CD68. Figure 1D shows a representative tis-
sue section from a metastatic melanoma lesion that was stained 
with MERTK and CD68 antibodies then counterstained with 
Hoechst 33258. Tissue studio analysis revealed that 53% of CD68+ 
tumor–infiltrating cells coexpress MERTK (range 0%–94%).
To further validate the MERTK expression trend observed at 
the protein level, MERTK transcript expression was assessed as 
a function of melanoma disease progression using a previously 
published melanoma microarray collection (21). Using microarray 
data collected from patient tissue samples, MERTK gene expres-
sion data were obtained from patient tissue samples derived from 
normal skin (n = 5), primary melanoma (n = 14), and metastatic 
melanoma (n = 40) tissue datasets (Figure 1E and Supplemental 
Table 1). Mean MERTK transcript levels increased with disease 
progression, and while there was no statistical increase in MERTK 
transcript expression between normal skin and primary tumors, 
there was a significant increase in MERTK mRNA expression in 
metastatic tumors compared with primary tumors (P < 0.05). In 
addition, MERTK mRNA in metastatic tumors was significantly 
greater than in normal skin (P < 0.05). Taken together, these data 
indicate that MERTK expression at both the transcript and protein 
levels increases with melanoma disease progression and suggest a 
role for MERTK in melanoma development and progression.
MERTK is overexpressed in melanoma cell lines and can be stimulated 
to activate MAPK, AKT, and JAK/STAT pathways. MERTK mRNA 
transcript levels assessed by microarray were evaluated using 2 cell 
line datasets. In a cell line collection that underwent microarray 
analysis at UNC, 55% (20 of 36) of melanoma cell lines had tran-
script levels greater than those in normal human melanocytes 
(Figure 2A and Supplemental Table 2). No significant correla-
tion was observed between MERTK expression and oncogenic 
mutations in RAS or BRAF (RASWT/BRAFWT, RASMutant, BRAFMutant, 
Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI67816DS1). The finding that 
approximately 50% of melanoma cell lines overexpress MERTK 
mRNA was confirmed by an independent analysis of microarray 
data obtained from melanoma cell lines available through the 
Cancer Cell Line Encyclopedia (CCLE); 46% (24 of 52) of cell lines 
overexpressed MERTK compared with normal skin and were inde-
pendent of molecular subtype (Supplemental Figure 1, B and C 
and Supplemental Table 3). Based on the mRNA levels observed 
in the microarray analyses of Figure 2A, a subset of cell lines with 
either high or low MERTK mRNA were selected for MERTK pro-
tein analyses by Western blot. As shown in Figure 2B, most cell 
lines with high MERTK mRNA levels exhibited similarly high 
MERTK protein levels, and all cell lines with low MERTK mRNA 
exhibited low MERTK protein levels, including 2 isolates of nor-
mal human melanocytes (NHM17 and NHM18). These results 
validate the microarray data and support the notion that MERTK 
mRNA transcript levels correlate with protein abundance.
Figure 2
Melanoma cell lines frequently express MERTK irrespective of oncogenic mutational status. (A) Microarray analysis of MERTK transcript levels 
in normal human melanocytes (NHM) and melanoma cell lines. Melanoma cell lines are grouped by oncogenic mutation status. Dotted line 
represents the average NHM MERTK transcript level. A complete list of melanoma cell lines analyzed is provided in Supplemental Table 2. (B) 
MERTK protein expression in melanoma cell lines. MERTK protein was detected in lysates from the indicated cell lines by Western blot. Actin 
was detected as a loading control.
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To study the role of MERTK in melanoma, 4 melanoma cell 
lines were selected that express MERTK and are representative 
of the most frequent melanoma molecular subtypes; G361 and 
SKMEL5 melanoma cells harbor the BRAFV600E activating muta-
tion, SKMEL119 harbors the NRASQ61R mutation, and HMCB 
expresses wild-type BRAF and RAS proteins. Studying the role of 
MERTK in the context of BRAF and NRAS mutations is impor-
tant from a clinical perspective, since approximately 50% and 20% 
of melanomas contain BRAF- and NRAS-activating mutations, 
respectively (22). To determine the expression of TAM-family 
RTKs, MERTK, TYRO3, and AXL protein expression was deter-
mined by Western blot analysis. As shown in Figure 3A, all 4 
melanoma cell lines expressed TYRO3 and MERTK; only 1 cell 
line (HMCB) weakly expressed AXL. The multiple MERTK spe-
cies observed are likely due to posttranslational modifications, 
most notably, glycosylation. MERTK has been described to be 
both heavily and differentially glycosylated through Asn-linked 
glycosylation (23, 24). Treatment of melanoma cell lysates with 
PNGase F resulted in 1 predominant lower molecular weight 
band (Supplemental Figure 2). To determine whether MERTK 
is active in these cells, phospho-MERTK levels in the 4 cell lines 
were identified. Immunoprecipitates were analyzed by Western 
blot using an antibody directed against the triphosphorylated 
MERTK activation loop (Figure 3B). All cell lines contained 
phosphorylated MERTK, suggesting that MERTK is an active 
receptor in these cells.
To determine signaling pathways that are activated down-
stream of MERTK, a phosphokinase array was employed as an 
exploratory tool to examine alterations in kinase signaling in 
response to GAS6 stimulation. In HMCB cells, p38, ERK1/2, 
Figure 3
Melanoma cell lines express TAM receptors and can be activated to promote antiapoptotic and prosurvival signaling. (A) TAM receptor expres-
sion in 4 metastatic melanoma cell lines. Lysates from HMCB, SKMEL119, G361, and SKMEL5 were analyzed by Western blot for MERTK, 
TYRO3, and AXL expression. GAPDH was detected as a loading control. (B) MERTK phosphorylation in melanoma cell lines. Subconfluent 
cultures were treated with pervanadate. MERTK was immunoprecipitated (IP) from whole-cell lysates then visualized by Western blot for 
phosphorylated MERTK. As a control, total MERTK protein was detected in whole-cell lysates corresponding to the protein load applied to 
the immunoprecipitation. (C) GAS6 activation of signaling pathways in melanoma cell lines. Phosphokinase array suggests p38, ERK1/2, 
GSK3α/β, AKT, AMPK, STAT5, CHK-2, FAK, and STAT6 as signaling molecules downstream of MERTK. Relative phosphorylation between 
control-treated and GAS6-treated cells is shown graphically for a subset of signaling molecules probed. (D) Western blot of phospho- and 
total STAT6, AKT, and ERK1/2. Cell cultures were stimulated with GAS6 and whole-cell lysates were evaluated by Western blot analysis. Actin 
was detected as a loading control.
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GSK3α/β, AKT, and FAK kinase were phosphorylated upon 
GAS6 treatment relative to control-treated cells (Figure 3C, left). 
Similarly, GSK3α/β, AKT, and FAK were activated in G361 cells 
(Figure 3C, right). In addition, AMPKα2, STAT5B, CHK2, and 
STAT6 were also stimulated in G361 cells relative to the con-
trol-treated cells. To confirm the phosphokinase array results, 
a subset of these signaling proteins was examined by Western 
blot. STAT6, ERK1/2, and AKT were indeed phosphorylated in 
both HMCB and G361 cell lines in response to GAS6 stimula-
tion (Figure 3D). Similar trends were observed in SKMEL119 
and SKMEL5 cells (Supplemental Figure 3). Overall, these data 
indicate that MERTK is frequently overexpressed in melanoma 
cells and that MERTK activation can regulate MAPK/ERK, PI3K/
AKT, and JAK/STAT pathways.
MERTK silencing by shRNA inhibits oncogenic properties in melanoma 
cells. To further investigate the role of MERTK in oncogenic sig-
naling and characterize the effects of long-term MERTK inhibi-
tion, we established MERTK knockdown melanoma cell lines. 
Figure 4
MERTK inhibition by shRNA diminishes MERTK-mediated downstream 
signaling, colony-forming potential, and tumorigenesis. (A) MERTK 
protein expression in cell lines stably expressing shRNA against 
MERTK. Whole-cell lysates from indicated cell lines were analyzed by 
Western blot for MERTK protein expression. Actin was detected as a 
loading control. (B) GAS6-mediated signaling in MERTK knockdown 
cell lines. shControl and MERTK knockdown cell lines were treated with 
GAS6 and downstream signaling was evaluated by Western blot. (C) 
Anchorage-independent colony-forming assays. Cell lines were grown 
in soft agar for 21 days (HMCB) or 14 days (G361) then stained and 
counted. Images from a representative experiment are shown. Mean 
values and standard errors were derived from at least 3 independent 
experiments. Statistically significant differences compared with shCon-
trol cells were determined using a Student’s 2-tailed t test (*P < 0.05; 
**P < 0.01; ***P < 0.001). (D) Tumor growth in HMCB xenograft mouse 
model. HMCB shControl and shMERTK1 cells were injected ectopically 
in mice. Tumor volume was monitored on the indicated days via caliper 
measurement, and the average tumor volume with standard deviation 
is plotted against the days after xenograft (*P < 0.05, n = 6).
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HMCB and G361 cells were transduced with one of two independent 
shRNAs targeting MERTK (shMERTK1 and shMERTK4) or an 
shRNA targeting an irrelevant gene (shControl) to produce stable 
MERTK knockdown derivative cell lines. As shown in Figure 4A, 
MERTK protein expression was reduced in cell lines expressing 
shMERTK constructs. This reduction in MERTK protein expres-
sion reduced GAS6-mediated downstream signaling through 
antiapoptotic and prosurvival signaling pathways including 
STAT6, AKT, and ERK1/2 (Figure 4B). The residual activation 
of these signaling proteins in GAS6-treated knockdown cells 
could be due to signaling mediated through other cell-surface 
TAM receptors or to residual MERTK expression. These results 
demonstrate that STAT6, AKT, and ERK1/2 phosphorylation in 
these melanoma cells is mediated by GAS6 activation of MERTK 
and that inhibition of MERTK with shRNA can attenuate sur-
vival and proliferation signaling.
To characterize the functional consequences of MERTK-mediated 
prosurvival and antiapoptotic signaling, the long-term effects of 
MERTK knockdown with shRNA were investigated. Using a soft agar 
assay, the role of MERTK in anchorage-independent growth of mel-
anoma cells was evaluated. Both HMCB and G361 cell lines trans-
duced with shMERTK constructs developed significantly fewer colo-
nies in soft agar compared with shControl cell lines (Figure 4C). For 
HMCB, colony numbers decreased by 44% for shMERTK1 (P < 0.01) 
and by 76% for shMERTK4 (P < 0.01) compared with shControl 
(Figure 4C, left). Similarly, G361 colony numbers decreased by 35% 
for shMERTK1 (P < 0.05) and by 59% for shMERTK4 (P < 0.001) 
compared with shControl (Figure 4C, right). To determine whether 
MERTK inhibition via shRNA knockdown could mitigate mela-
noma tumorigenic potential in vivo, HMCB cells were injected sub-
cutaneously into the flanks of SCID mice. At 26 days after implanta-
tion, HMCB shMERTK1 xenograft tumors had 60% smaller tumor 
volumes (73 mm3 mean tumor volume) compared with shControl 
tumors (183 mm3 mean tumor volume, P < 0.05) (Figure 4D). These 
in vitro and in vivo data indicate that MERTK plays important roles 
in the oncogenic/tumorigenic melanoma phenotype and suggest 
that MERTK is a therapeutic target in melanoma.
A novel MERTK tyrosine kinase inhibitor, UNC1062, inhibits MERTK-
mediated signaling, promotes apoptosis, and inhibits colony formation in 
melanoma cells. While activating mutations in BRAF and NRAS 
occur in melanoma at rates of 41% and 18%, respectively (25), 
lower mutation frequency or gene amplifications in other signal-
ing molecules, such as RTKs, can also contribute to melanoma 
pathogenesis (26–28). UNC1062 was developed as a MERTK- 
selective tyrosine kinase inhibitor (Figure 5A). Its structure is 
based on a previously published pyrazolopyrimidine scaffold (29), 
and it has an improved affinity and specificity profile compared 
with its parent compound, UNC569 (Liu and Wang, unpublished 
observation). UNC1062 potently inhibits MERTK kinase activity 
in vitro (MERTK IC50 = 1.1 nM, Morrison Ki = 0.33 nM) and exhib-
its specificity within the TAM family (TYRO3 IC50 = 60 nM, AXL 
IC50 = 85 nM). Treatment of HMCB and G361 cells with increasing 
concentrations of UNC1062 resulted in a potent dose-dependent 
reduction in MERTK phosphorylation (Figure 5B).
To assess the impact of pharmacological MERTK inhibition 
on downstream signaling, MERTK-mediated signaling was eval-
uated in the presence of UNC1062. HMCB and G361 cells were 
pretreated with 1 μM UNC1062 or vehicle for 90 minutes prior 
to stimulation with GAS6 or vehicle only. As shown in Figure 5C, 
cells treated with vehicle exhibited MERTK-mediated activation of 
STAT6, AKT, and ERK1/2. In contrast, treatment with UNC1062 
greatly diminished activation of these signaling molecules.
The consequence of inhibiting MERTK-mediated antiapop-
totic and prosurvival signaling pathways was investigated by 
monitoring cell death. Induction of apoptosis in response to 
treatment with UNC1062 was measured by flow cytometric 
analysis of cells stained with YO-PRO-1 iodide and propid-
ium iodide (PI), dyes that are selectively taken up by apoptotic 
(YO-PRO-1+) and/or dead (YO-PRO-1+, PI+) cells. HMCB cell 
death increased 9%, while G361 cell death increased 22% after 
treatment with UNC1062 compared with vehicle-treated cells 
(Figure 6A). Cell death following treatment with UNC1062 was 
confirmed by Western blot analysis showing increased PARP 
cleavage in both melanoma cell lines (Figure 6B). These data 
Figure 5
UNC1062 is a novel MERTK inhibitor that reduces MERTK-mediated antiapoptotic and prosurvival downstream signaling. (A) Chemical struc-
ture of UNC1062. (B) Inhibition of phospho-MERTK with UNC1062. Subconfluent cultures were treated with indicated doses of UNC1062 for 
90 minutes followed by pervanadate treatment. MERTK was immunoprecipitated from whole-cell lysates then visualized by Western blot for 
phosphorylated MERTK and total MERTK. (C) Downstream signaling inhibition after administration of UNC1062. Cultures were serum starved 
then treated with UNC1062 for 90 minutes. After treatment with UNC1062, cells were stimulated with GAS6 and lysates were analyzed by Western 
blot for phospho- and total STAT6, AKT, and ERK1/2. GAPDH was detected as a loading control.
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suggest that pharmacologic inhibition of MERTK can reduce 
oncogenic signaling and promote apoptosis in melanoma cells 
regardless of BRAF mutation status.
To determine whether pharmacologic MERTK inhibition can 
abrogate melanoma cell oncogenic properties, the effect of treat-
ment with UNC1062 on colony formation was determined. For 
these studies, HMCB and G361 soft agar cultures were treated 
with UNC1062 or vehicle only. As shown in Figure 7A, treatment 
with 0.5 μM or 1.0 μM UNC1062 resulted in a statistically sig-
nificant reduction in colony formation relative to vehicle-treated 
controls in both HMCB cells (62% and 97%, respectively) and G361 
cells (68% and 95%, respectively).
MERTK inhibition reduces migration and invasion of melanoma cells. To 
assess the impact of MERTK inhibition on migration and invasion, 
the SKMEL119 cell line, which has substantial growth and invasive 
capacity, was used. SKMEL119 cells express elevated MERTK lev-
els that are markedly diminished by the expression of shMERTK4 
(Supplemental Figure 4A). Time-lapsed video microscopy was used 
to measure cell migration of shControl and shMERTK4-expressing 
SKMEL119 cells across a fibronectin-coated surface. A statistically 
significant 30% decrease in the velocity of individual cell migration 
was observed in cells expressing shMERTK4 relative to shControl 
cells (Supplemental Figure 4B). Additionally, using a 3D collagen 
matrix invasion assay (30), spheroids of SKMEL119 treated with 
UNC1062 exhibited an 89% reduction in invasion (P < 0.001, Figure 
7B). These results demonstrate that MERTK inhibition by either 
MERTK knockdown or treatment with UNC1062 reduces migra-
tion and invasion of melanoma cells.
Discussion
Despite the recent FDA approval of vemurafenib and ipilimumab, 
treatment of patients with metastatic melanoma remains chal-
lenging due to the primary resistance to chemotherapies and 
molecularly targeted therapies, the development of acquired 
resistance to BRAF inhibitors, or to the limited benefit of immu-
notherapies to a small subgroup of patients. Recent advances in 
next-generation sequencing of melanoma have confirmed earlier 
observations that only a handful of genes bear mutations or copy 
number alterations at a frequency of greater than 20% (31). There-
fore, it is critical to identify other important potential targets in 
melanoma development and progression that are amenable to 
pharmacological inhibition. The studies presented here add mel-
anoma to the growing list of malignancies in which MERTK is 
aberrantly expressed. We believe this work has led to several novel 
insights. First, MERTK expression is significantly elevated in 
distant metastatic tumors compared with primary melanomas. 
Second, MERTK is overexpressed in approximately half of mela-
noma cell lines, irrespective of BRAF and NRAS status, and is an 
active receptor. Third, targeting MERTK suppresses prosurvival 
pathways such as STAT6, AKT, and ERK1/2. Fourth, targeting 
MERTK suppresses colony-forming potential and migration. And 
fifth, targeting MERTK in vivo retards tumor growth in a human 
melanoma xenograft model.
The finding that MERTK expression is highest in distant met-
astatic melanomas compared with primary melanomas and the 
roles of MERTK in colony formation, migration, and invasion 
suggest that MERTK plays a role in the progression of primary 
Figure 6
MERTK inhibition with UNC1062 increases apoptosis in melanoma cell lines. (A) YO-PRO-1/PI staining and flow cytometric analysis. Cells 
were treated with the indicated doses of UNC1062 for 48 hours and then stained with YO-PRO-1 iodide (YO-PRO-1) and PI. Stained cells were 
analyzed on a flow cytometer to determine uptake of YO-PRO-1 and PI in apoptotic and dead cells. Mean values and standard errors were deter-
mined from 3 independent experiments. Statistically significant differences relative to vehicle only were determined using a Student’s 2-tailed 
t test (*P < 0.05). Representative scatter plots and percentages of early apoptotic (bottom right region) and dead (upper region) cells are shown 
for control- and UNC1062-treated cells. (B) PARP cleavage. Cells were treated with the indicated dose of UNC1062 for 24 hours and lysates were 
analyzed via Western blot.
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melanomas and the development of distant metastases. Similar to 
the observations in this report, the migratory nature of glioblas-
toma cells could be reduced by MERTK inhibition with either 
shRNA knockdown or a MERTK monoclonal antibody (15), sug-
gesting that increased MERTK expression may contribute to out-
growth of the metastatic tumor.
In agreement with a previous report demonstrating phos-
phorylation of TAM family receptors in several melanoma cell 
lines (16), the data presented here confirm that MERTK can 
be phosphorylated in melanoma cells and further show that 
MERTK is functionally important for several oncogenic signal-
ing pathways and phenotypes. Specifically, we report here on 
MERTK-mediated signaling through the MAPK/ERK, PI3K/
AKT, and JAK/STAT signaling pathways. The mechanism of 
MERTK activation in melanoma cells is not clear, but Sensi et al. 
have previously described melanoma cell expression and secre-
tion of GAS6, the common ligand for all members of the TAM 
family of proteins, suggesting a method of autocrine and/or 
paracrine activation of MERTK (18). Since expression of MERTK 
by melanoma cells increases during progression from primary 
to metastatic melanoma, it would be interesting to determine 
whether corresponding increases in GAS6 levels occur in serum 
from patients with metastatic melanoma, implicating serum 
GAS6 levels as a potential early marker of melanoma progres-
sion, as in other cancers (32).
MAPK/ERK and PI3K/AKT are 2 of the most frequently dys-
regulated pathways in melanoma (31). These 2 pathways not 
only play a role in melanoma development and progression, but 
are also involved in primary and secondary resistance to BRAF 
inhibitors (5–8). The observation that MERTK signals via both 
Figure 7
MERTK inhibition reduces colony-forming potential and 
migratory and invasive capabilities. (A) Anchorage-indepen-
dent colony-forming assays. HMCB and G361 were grown in 
soft agar with the indicated doses of UNC1062. Images from 
a representative experiment are shown. Mean values and 
standard errors were derived from at least 3 independent 
experiments. Statistically significant differences were deter-
mined using a Student’s 2-tailed t test (***P < 0.001). (B) 
Invasion of SKMEL119. Cells were grown into spheroids and 
the spheroids were transplanted into collagen matrix and 
evaluated for invasion after 96 hours. Images from a repre-
sentative experiment are shown. Original magnification, ×40. 
Bar graphs show means and standard errors derived from 6 
spheroids (Student’s 2-tailed t test, ***P < 0.001).
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in Bond dewax solution (AR9222) and hydrated in Bond wash solution 
(AR9590). Antigen retrieval for all antibodies was performed for 30 min-
utes at 100°C in Bond epitope retrieval solution 1 (AR9961, pH 6.0). 
Primary antibodies were applied sequentially and slides were incubated 
with the MERTK antibody (Epitomics Y323, 1:1,000), followed by Bond 
polymer (DS9800) and the tyramide Cy5 amplification step to visual-
ize MERTK (PerkinElmer). After completion of MERTK staining, the 
primary antibodies against S100 (Dako) or CD68 (Leica Microsystems) 
were applied. S100 was detected with Alexa555-labeled goat anti-rabbit 
secondary antibody (Invitrogen) and CD68 with goat anti–mouse-HRP 
(EnVision+, Dako), followed by tyramide Cy3 (PerkinElmer). Nuclei 
were stained with Hoechst 33258 (Invitrogen). The stained slides were 
mounted with ProLong Gold antifade reagent (Molecular Probes, Inc.). 
For immunohistochemistry slides were incubated with MERTK anti-
body (Epitomics, 1:500) followed by Bond Polymer Refine Red Detection 
(DS9390), including hematoxylin counterstain.
Imaging analyses. AQUA analysis software, version 2.2 (HistoRx) was used 
to assess MERTK expression in S100-positive cells. Briefly, high-resolu-
tion acquisition (×20 objective) of TMA immunofluorescence (IF) slides 
in the DAPI (Hoechst 33258), Cy3 (S100), and Cy5 (MERTK) channels 
was performed using a PM-2000 (HistoRx), as described (34). The AQUA 
algorithm was used to score the expression of MERTK in an S100 mask, a 
melanocyte lineage marker. Monochromatic and merged high-resolution 
(512 × 512 pixel, 1-μm resolution) images for each spot were generated. 
Tissue Studio analysis (Definiens Architect XD v2.0.4, Tissue Studio v3.5) 
was used to assess the percentage of MERTK expression in melanoma- 
infiltrating CD68+ cells. Briefly, a TMA IF slide was scanned in Aperio FL 
(Aperio Technologies) through DAPI (Hoechst 33258), Cy3 (CD68), and 
Cy5 (MERTK) channels using a ×20 objective. The Tissue Studio image 
analysis solution was then applied using the DAPI channel to define the 
cell nucleus and the Cy5 channel to define the cell membrane. The ratio of 
cells that coexpress DAPI, Cy3, and Cy5 divided by the cells that coexpress 
DAPI and Cy3 was used to calculate the percentage of MERTK+CD68+ mel-
anoma-infiltrating cells.
Gene expression analysis. Raw microarray gene expression profiles were 
obtained from the NCBI Gene Expression Omnibus (GEO) (35) for 
GSE36133 (36) and GSE7553 (21) datasets. Robust multiarray average 
(RMA) (37) was performed on these Affymetrix datasets to extract signal 
intensities and perform data normalization using the Affymetrix Power 
Tools program. The GSE36133 dataset was analyzed independently and 
the 5 normal skin samples were normalized with the 61 melanoma cell 
lines from GSE7553 using RMA. Mutation data for the 61 melanoma cell 
lines were assessed by examination of the CCLE project website (36) for each 
cell line; data for duplicate cell lines were averaged and cell lines without 
mutation data were excluded from further analysis. We also obtained the 
normalized data for GSE40047 (38), profiled by Agilent-014850 Whole 
Human Genome Microarray 4x44K G4112F. Melanoma cell lines or nor-
mal melanocyte lines were labeled as Cy5, and reference RNA was labeled 
as Cy3. The normalized/processed data obtained from the GEO for this 
dataset were expressed as –log10(Cy3/Cy5). The arrays were scanned and log2 
ratios were generated for each gene. The data were median normalized by 
subtracting out the median log-ratio for each array so that each normalized 
array had a median log-ratio of 0. Values for the gene of interest were deter-
mined and a constant was added to each gene value to adjust the lowest 
value of each array to 0. Each value was then used as an exponent to 2 (i.e., 
2x) to transform the values into fold change from the log2 value generated 
from the arrays. This set the lowest value in each dataset to 1, and all of the 
other values represented the fold change difference from the lowest value. 
Mutational status for this dataset was obtained from the GEO. MERTK 
expression was extracted and plotted across cell lines for comparison.
pathways, as well as through others whose roles in melanoma 
biology are currently unclear (e.g., STAT6), not only highlights 
the complex regulation of these pathways by membrane recep-
tors, such as MERTK, but may also provide a therapeutic advan-
tage, since targeting MERTK may disrupt signaling in multiple 
pathways. These observations and the data presented here suggest 
that MERTK-targeted therapies could potentially be considered 
for patients, irrespective of BRAF and NRAS status and/or prior 
treatment with BRAF inhibitors.
MERTK is expressed at high levels in melanoma-infiltrating 
CD68+ cells, and the role of MERTK in this context warrants 
further investigation in view of early observations that MERTK 
knockout mice frequently exhibit autoimmune phenomena due 
to their inability to engulf and efficiently clear apoptotic cells 
(20). Since the development of autoimmunity has been associ-
ated with clinical benefit in melanoma (33), it is tempting to 
speculate that increased expression of MERTK in melanoma- 
infiltrating macrophages increases the efficiency of macro-
phages to clear apoptotic melanoma cells and thereby limits 
the time for antigens released by dying cells to stimulate the 
immune system to develop an effective antitumor response. 
With respect to this hypothesis, targeting MERTK may poten-
tially have a dual antitumor role; first by directly inhibiting 
migration, invasion, and growth of tumor cells, and also by an 
indirect immunomodulatory role.
To our knowledge, this study is the first to characterize roles 
for MERTK in melanoma and provide proof-of-principle studies 
toward establishing MERTK as a therapeutic target in melanoma 
by using the MERTK-specific small-molecule inhibitor, UNC1062. 
The increased expression of MERTK in a large (greater than 30%) 
number of metastatic melanomas, its potent effect in migration, 
invasion, and colony formation that is unrelated to the presence of 
BRAF and NRAS mutations, its signaling via multiple intracellular 
pathways that are known to be oncogenic, its potential roles in 
other host cells, and the development of highly specific small-mol-
ecule inhibitors provide the rationale and the means for continued 
development of a MERTK-targeted therapeutic agent for the treat-
ment of malignant melanoma.
Methods
Melanoma tissue microarrays and other tissues. The previously described 
nevus-to-melanoma progression TMA was stained to assess the expression 
of MERTK in nevi, primary, and metastatic melanomas (19). The Univer-
sity of North Carolina (UNC69A1) metastatic melanoma TMA was cre-
ated from specimens obtained from the UNC Hospital surgical pathology 
archive under the protocol approved by the UNC Institutional Review 
Board (08-0242). TMA was stained to assess the expression of MERTK in 
mononuclear as well as melanoma cells in melanomas metastatic to brain 
(n = 11), lung (n = 8), liver (n = 4), and stomach (n = 1). The UNC69A1 TMA 
was constructed from representative tumor cores (0.6-mm) spotted in trip-
licate, and 4-micron-thick sections were used for further analysis. Forma-
lin-fixed paraffin-embedded tumor blocks from patients who underwent 
craniotomy for melanoma brain metastases at the University of Pittsburgh 
Medical Center (UPMC) were retrieved under the University of Pittsburgh 
Cancer Institute’s (UPCI) IRB-approved protocol 10-005 and 5-micron sec-
tions were available for further analysis.
Immunofluorescence and immunohistochemistry. Dual immunofluores-
cent stains of TMA slides with antibody pairs of either MERTK-S100 
or MERTK-CD68 were carried out using the Bond fully automated 
slide-staining system (Leica Microsystems). Slides were de-paraffinized 
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Invitrogen). YO-PRO-1 and PI uptake was analyzed using a Beckman 
Coulter Gallios flow cytometer and CXP and/or Kaluza software. Cells 
were plated and treated in the same manner for PARP cleavage assays, 
but cells were lysed after collection.
Migration assays. SKMEL119 cells were plated on MatTek dishes coated 
with 10 μg/ml of fibronectin in PBS and allowed to attach overnight. 
Cells were subsequently equilibrated in a VivaView FL microscope 
(Olympus) live-cell imaging chamber at 37°C for 1 hour followed by 
time-lapse imaging of 25 viewing fields from each dish. Images were 
taken of each field every 40 minutes for 16 hours (original magnifica-
tion, ×200) and were converted to stacks using ImageJ software (NIH). 
Single-cell velocity was measured with ImageJ software (NIH) using the 
Manual Tracking plug-in. Cells that divided, migrated out of field of 
view, or touched other cells more than transiently were excluded from 
the analysis.
Invasion assays. SKMEL119 spheroids were grown by plating cells 
(5 × 103) in DMEM supplemented with 30% FBS in a 96-well plate 
coated with 1.5% noble agar. After 72 hours, spheroids were harvested 
then implanted into a gel of bovine collagen I containing 1× EMEM 
supplemented with 10% FBS and DMSO or UNC1062 in 24-well plates. 
DMEM containing either DMSO or drug was layered over the solid-
ified collagen. Spheroids were allowed to invade the collagen for 96 
hours before images were taken. Relative units of invasive growth were 
determined using area measurement tools in Adobe Reader 9 Pro and 
subtracting initial spheroid size. Experiments were performed 3 times, 
with 6 spheroids/invasions analyzed from duplicate wells for each con-
dition in each experiment.
Statistics. For the analysis of TMA data, R package and GraphPad Prism 5 
(GraphPad) software were used. The MERTK TMA AQUA scores were log 
transformed for normality. A 1-way ANOVA was performed to compare 
the association between nevi, primary melanomas, and metastatic mela-
nomas. Linear regression was fitted to MERTK expression to assess the 
significance of the trend in MERTK expression across different stages of 
nevus-to-melanoma progression.
Data from all in vitro experiments are reported as the mean ± SEM 
unless otherwise noted. Data were analyzed and presented using Graph-
Pad Prism 5 software (GraphPad). Significance was determined using a 
Student’s 2-tailed t test unless otherwise noted.
Results were considered significant at P values less than 0.05 and are 
labeled with a single asterisk. In addition, P values less than 0.01 and less 
than 0.001 are designated with double and triple asterisks, respectively.
Study approval. The UNC metastatic melanoma TMA (UNC69A1) 
was developed under the UNC’s IRB-approved protocol 08-0242 
(Chapel Hill, North Carolina, USA). Melanoma brain metastasis sam-
ples were collected at the UPMC and were retrieved under the UPCI’s 
IRB-approved protocol 10-005 (Pittsburgh, Pennsylvania, USA). Ani-
mal experiments were performed under an approved UNC Institu-
tional Animal Care and Use Committee protocol. (Chapel Hill, North 
Carolina, USA).
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Cell culture and reagents. HMCB was propagated in RPMI medium 
supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin 
(100 μg/ml). G361, SKMEL5, and SKMEL119 were cultured in DMEM 
and supplemented as described above. HMCB, G361, SKMEL5, and 
A2058 identities were verified by short tandem repeat (STR) analy-
sis and matched ATCC product information. At this time there is no 
STR profile publicly available for SKMEL119, WM1232, SKMEL27, 
SKMEL23, UACC257, SKMEL24, SKMEL130, SKMEL131, SKMEL23, 
SKMEL178, or SKMEL186; however, the STR profiles are singular and 
do not match any in the ATCC or DSMZ collections. Pervanadate solu-
tion containing 10 nM sodium orthovanadate and 0.15% H2O2 was 
prepared. UNC1062 inhibitor was synthesized based on a published 
patent procedure by Wang et al. (39), and stock solutions were pre-
pared in DMSO at 3 mM.
Western blot and signaling assays. Whole-cell lysates were prepared in 
lysis buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 10 mM 
EDTA, 10% glycerol, 1% Triton X-100, 1 mM Na3VO4, 0.1 mM Na2MoO4, 
1 mM NaF, and protease inhibitors (Roche). Equal protein amounts 
were separated on 8% Tris-glycine SDS-PAGE then transferred to PVDF 
or nitrocellulose membranes. Antibodies were applied according to the 
manufacturer’s specifications (Supplemental Table 4). For GAS6 stimu-
lation studies, cells (4 × 105) were incubated overnight and then starved 
for 3 hours in serum-free medium prior to activation with either 200 nM 
GAS6 (885-GS; R&D Systems) or control buffer for 10 minutes. 
UNC1062 signaling inhibition studies were conducted in a similar 
manner but included the addition of drug after 2 hours of serum star-
vation and treatment for 90 minutes prior to activation with GAS6. 
Due to the short lifetime of MERTK phosphorylation in vitro, a perva-
nadate treatment was used only to observe levels of phospho-MERTK. 
For phospho-MERTK assays, subconfluent cultures were treated with 
pervanadate solution for 3 minutes, MERTK was immunoprecipitated 
from whole-cell lysates (MAB8912; R&D Systems) then visualized 
with Western blot using p-MERTK antibody (PhosphoSolutions) (11). 
PNGase F was conducted according to the manufacturer’s instructions 
(P0704; New England BioLabs). All Western blots are a representative 
example of at least 3 independent experiments. The phosphokinase 
array was performed once according to the manufacturer’s instructions 
(ARY003; R&D Systems).
Stable shRNA cell line production. Constitutive shRNA cell lines (HMCB, 
SKMEL119, G361 shMERTK1, and shMERTK4) were developed as pre-
viously described (11). Control cell lines were produced in a similar man-
ner with either an shRNA against the human ERBB4 gene (HMCB and 
SKMEL119) or GFP (G361).
Colony formation assays. Cells were plated in approximately 0.3% agar over 
a higher percentage agar base layer. Agar was overlaid with medium (RPMI 
for HMCB and McCoys for G361). Colonies were grown for 14 to 21 days 
prior to staining with 1 mg/ml nitrotetrazolium blue (Sigma-Aldrich) and 
subsequent counting. Medium and UNC1062 were renewed twice weekly. 
Medium was renewed after 7 days for shRNA experiments.
Mouse xenograft models. HMCB shControl and shMERTK1 cells (3 × 106 
in 100 μl) were injected subcutaneously into the flanks of 8- to 9-week-old 
female SCID mice (n = 6 per group). Tumor growth was monitored twice 
weekly using calipers, and tumor volume was calculated using a modified 
ellipsoid model (π/6 × length × width × depth).
Apoptosis assays. Cells (1 × 105) were plated and incubated overnight 
prior to treatment with UNC1062 or an equivalent concentration of 
DMSO. After 48 hours of treatment, cells were lifted with 0.02% EDTA 
in PBS and combined with cell culture supernatant. Cells were collected 
by centrifugation and resuspended in PBS containing 0.5 μM YO-PRO-1 
(Y3603; Invitrogen) and 0.5 μg/ml propidium iodide (PI) (P3566; 
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